/CLDX
CLDX Stock - Celldex Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$25.60+1.23%
+$0.31 (+1.23%) • Dec 19
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.64
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).32
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.75
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-8.9%upside
Target: $23.32
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CLDX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$25.34 – $25.86
TARGET (TP)$23.33
STOP LOSS$23.55
RISK/REWARD1:-1.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.14
52W High$30.50
52W Low$14.40
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.02M | $6.88M | $2.36M | $4.65M | $7.42M |
| Gross Profit | $-156,530,000 | $-111,128,000 | $-79,901,000 | $-48,660,000 | $-35,116,000 |
| Gross Margin | -2229.8% | -1614.5% | -3389.9% | -1046.2% | -473.4% |
| Operating Income | $-195,078,000 | $-154,542,000 | $-115,234,000 | $-71,243,000 | $-63,354,000 |
| Net Income | $-157,863,000 | $-141,429,000 | $-112,325,000 | $-70,511,000 | $-59,780,000 |
| Net Margin | -2248.8% | -2054.8% | -4765.6% | -1516.0% | -805.9% |
| EPS | $-2.45 | $-2.92 | $-2.40 | $-1.64 | $-2.02 |
Company Overview
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
7
78%
Hold / Neutral
2
22%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish2 Neutral/Bearish
Price Targets
$45
Average Target
↑ 77.2% Upside
Now
$21
Low
$45
Average
$70
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 21st 2025 | Mizuho | Initiation | Outperform | $48 |
| October 13th 2025 | Barclays | Initiation | Underweight | $25 |
| April 28th 2025 | Canaccord Genuity | Initiation | Buy | $64 |
| March 20th 2025 | Morgan Stanley | Initiation | Overweight | $46 |
| February 13th 2025 | UBS | Initiation | Buy | $44 |
| October 7th 2024 | Citigroup | Initiation | Buy | $70 |
| September 30th 2024 | Goldman | Initiation | Neutral | $45 |
| September 27th 2024 | Wolfe Research | Downgrade | Peer Perform | - |
| June 18th 2024 | Stifel | Initiation | Buy | $58 |
| June 11th 2024 | Wolfe Research | Initiation | Outperform | $51 |
| December 20th 2023 | TD Cowen | Initiation | Outperform | - |
| November 10th 2023 | Wells Fargo | Upgrade | Equal Weight | $27 |
| August 22nd 2023 | Wells Fargo | Initiation | Underweight | $21 |
Earnings History & Surprises
CLDXBeat Rate
50%
Last 18 quarters
Avg Surprise
-0.9%
EPS vs Estimate
Beats / Misses
9/7
2 met exactly
Latest EPS
$-1.01
Q4 2025
EPS Surprise History
Q1 24
+25.0%
$-0.57vs$-0.76
Q2 24
+16.4%
$-0.56vs$-0.67
Q3 24
+8.5%
$-0.54vs$-0.59
Q4 24
+7.2%
$-0.64vs$-0.69
Q1 25
+2.7%
$-0.71vs$-0.73
Q2 25
-8.0%
$-0.81vs$-0.75
Q3 25
+1.2%
$-0.85vs$-0.86
Q4 25
-14.8%
$-1.01vs$-0.88
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-1.00 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.88 | $-1.01 | -14.8% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.86 | $-0.85 | +1.2% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.75 | $-0.81 | -8.0% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.73 | $-0.71 | +2.7% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.69 | $-0.64 | +7.2% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.59 | $-0.54 | +8.5% | ✓ BEAT |
Q2 2024 | May 6, 2024 | $-0.67 | $-0.56 | +16.4% | ✓ BEAT |
Q1 2024 | Feb 26, 2024 | $-0.76 | $-0.57 | +25.0% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $-0.67 | $-0.81 | -20.9% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.65 | $-0.65 | 0.0% | = MET |
Q2 2023 | May 4, 2023 | $-0.63 | $-0.62 | +1.6% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.59 | $-0.56 | +5.1% | ✓ BEAT |
Q4 2022 | Nov 9, 2022 | $-0.57 | $-0.57 | 0.0% | = MET |
Q3 2022 | Aug 8, 2022 | $-0.43 | $-0.58 | -34.9% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.46 | $-0.49 | -6.5% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.42 | $-0.43 | -2.4% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.35 | $-0.39 | -11.4% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.40 | $-0.34 | +15.0% | ✓ BEAT |
Latest News
Barclays Maintains Underweight on Celldex Therapeutics, Raises Price Target to $24
➖ NeutralBenzinga•Dec 17, 2025, 05:38 PM•Also:
Celldex Initiates Global Phase 3 Trial To Establish Efficacy And Safety Of Barzolvolimab In Adult Patients With ColdU And SD Who Remain Symptomatic Despite H1 Antihistamine Treatment
📈 PositiveBenzinga•Dec 9, 2025, 01:10 PM
Barclays Maintains Underweight on Celldex Therapeutics, Lowers Price Target to $21
📉 NegativeBenzinga•Nov 11, 2025, 03:03 PM•Also:
Celldex Therapeutics Q3 EPS $(1.01) Misses $(0.91) Estimate
📉 NegativeBenzinga•Nov 10, 2025, 09:46 PM
Celldex Releases New Exploratory Data From Its Phase 2 Study Showing That Barzolvolimab Improves Urticaria Control In Patients With Chronic Spontaneous Urticaria
📈 PositiveBenzinga•Nov 6, 2025, 01:21 PM
Celldex Releases Phase 1 Results For Its Bispecific Antibody CDX-622 Showing Drug Was Well Tolerated, Showed Favorable Pharmacokinetics, And Led To Rapid, Sustained Reductions In Serum Tryptase, Confirming Effective Mast Cell Inhibition
📈 PositiveBenzinga•Oct 30, 2025, 08:14 PM
Mizuho Initiates Coverage On Celldex Therapeutics with Outperform Rating, Announces Price Target of $48
📈 PositiveBenzinga•Oct 21, 2025, 12:44 PM
Barclays Initiates Coverage On Celldex Therapeutics with Underweight Rating, Announces Price Target of $25
📉 NegativeBenzinga•Oct 13, 2025, 12:17 PM•Also:
Canaccord Genuity Maintains Buy on Celldex Therapeutics, Maintains $62 Price Target
📈 PositiveBenzinga•Sep 17, 2025, 01:35 PM•Also:
Celldex Presents Phase 2 Data Showing Barzolvolimab Improves Chronic Spontaneous Urticaria Independent Of Baseline Immunoglobulin E Levels At EADV 2025
📈 PositiveBenzinga•Sep 17, 2025, 09:14 AM
Wells Fargo Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $38
➖ NeutralBenzinga•Aug 20, 2025, 06:47 PM•Also:
Citigroup Maintains Buy on Celldex Therapeutics, Lowers Price Target to $48
📈 PositiveBenzinga•Aug 20, 2025, 04:06 PM•Also: ,
Canaccord Genuity Maintains Buy on Celldex Therapeutics, Lowers Price Target to $62
➖ NeutralBenzinga•Aug 20, 2025, 01:54 PM•Also: ,
Celldex Therapeutics shares are trading lower after the company announced it has halted the development of EoE. Also, HC Wainwright & Co. cut its price target on the stock from $50 to $42.
📉 NegativeBenzinga•Aug 20, 2025, 12:24 PM•Also:
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Lowers Price Target to $42
➖ NeutralBenzinga•Aug 20, 2025, 10:42 AM•Also:
Celldex Therapeutics shares are trading lower. The company reported Phase 2 topline results for Barzolvolimab in Eosinophilic Esophagitis.
📉 NegativeBenzinga•Aug 19, 2025, 08:05 PM
Celldex Reports Phase 2 Topline Results For Barzolvolimab In Eosinophilic Esophagitis; Says Study Met Primary Endpoint Demonstrating Barzolvolimab's Ability To Potently Deplete Mast Cells In Gastrointestinal Tract
📈 PositiveBenzinga•Aug 19, 2025, 08:03 PM
Frequently Asked Questions about CLDX
What is CLDX's current stock price?
Celldex Therapeutics, Inc. (CLDX) is currently trading at $25.60 per share. The stock has moved +1.23% today.
What is the analyst price target for CLDX?
The average analyst price target for CLDX is $23.33, based on 1 analyst.
What sector is Celldex Therapeutics, Inc. in?
Celldex Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CLDX's market cap?
Celldex Therapeutics, Inc. has a market capitalization of $1.70 billion, making it a small-cap company.
Does CLDX pay dividends?
No, Celldex Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
BHVN
Biohaven Ltd.
$10.85
Mkt Cap: $1.1B
HRMY
Harmony Biosciences Holdings, Inc.
$37.81
Mkt Cap: $2.2B
IMNM
Immunome, Inc.
$21.44
Mkt Cap: $2.0B
JANX
Janux Therapeutics, Inc.
$13.79
Mkt Cap: $0.8B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
QURE
uniQure N.V.
$23.99
Mkt Cap: $1.3B
SION
Sionna Therapeutics, Inc.
$42.37
Mkt Cap: $1.9B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
Explore stocks similar to CLDX for comparison